Study: Drug-coated balloons beat plain balloon angioplasty in peripheral vessel disease

Drug-coated balloon treatments reduce the risk of target lesion revascularization in treating femoropopliteal artery disease by 67% when compared to plain balloon angioplasty procedures, according to a new study.

Results from the study were published in the Journal of the American College of Cardiology: Cardiovascular Interventions.

The study aimed to compared the risk of target lesion revascularization and all-cause death at 12 months with the 2 different treatments, with secondary objectives that included identifying factors that could have influenced general findings.

A total of 8 trials which compared DCB and PB procedures for femoropopliteal artery disease were examined in the study.

Risk of death was similar between groups while those treated with DCB showed a marked 12-month TLR risk. Long-term outcomes assessments showed reduced incidences of TLR with DCB and a similar incidence of all-cause death.

“DCB significantly reduces the risk of TLR as compared with PB without any effect on all-cause death. Evidence exists for differential efficacy according to the type of device used. Future trials investigating DCB angioplasty should include potentially more effective comparator therapies,” study authors wrote.

The post Study: Drug-coated balloons beat plain balloon angioplasty in peripheral vessel disease appeared first on MassDevice.

from MassDevice http://ift.tt/2bk3QRx